Please select the eligibility criteria that correspond to the clinical trial below.
Title: AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia.

PURPOSE: Thisphase III trial is studying several different combination chemotherapy regimens to compare how well they work in treating young patients with acute lymphoblastic leukemia.


Options:
A: Inclusion Criteria:

* Childhood ALL
* All mandatory biological data are available6
* Written informed consent has been obtained

Exclusion Criteria:

* Bilineage ALL
* Pre-treatment with glucocorticosteroids or other antileukemic agents for more than 1 week
* ALL predisposition syndromes
* Previous cancer
* Off protocol administration of additional chemotherapy during induction therapy
* Sexually active females not using contraception
* No allergic reactions to PEG Asparaginase
B: Inclusion Criteria:

* Histological diagnosis of nasopharyngeal carcinoma WHO type II or III

  * Stage I-IV disease
  * Newly diagnosed disease
* Performance status

  * Patients ≤ 16 years of age: Lansky 60-100%
  * Patients \> 16 years of age: Karnofsky 60-100%
* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min
* Creatinine based on age/gender as follows:

  * No greater than 0.4 mg/dL (for patients 1 month to \< 6 months of age)
  * No greater than 0.5 mg/dL (for patients 6 months to \< 1 year of age)
  * No greater than 0.6 mg/dL (for patients 1-2 years of age)
  * No greater than 0.8 mg/dL (for patients \< 6 years of age)
  * No greater than 1.0mg/dL (for patients 6 to \< 10 years of age)
  * No greater than 1.2 mg/dL (for patients 10 to \< 13 years of age)
  * No greater than 1.4 mg/dL (for female patients 13 to ≥ 16 years of age)
  * No greater than 1.5 mg/dL (for male patients 13 to \< 16 years of age)
  * No greater than 1.7 mg/dL (for male patients ≥ 16 years of age)
* Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
* AST or ALT \< 2.5 times ULN for age
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma
C: Inclusion Criteria:

* Histologically confirmed acute lymphoblastic leukemia (ALL)
* No secondary ALL
* More than 4 weeks since prior chemotherapy
* More than 4 weeks since prior steroids

Exclusion Criteria:

* Prior disease that would preclude treatment with chemotherapy
D: Inclusion Criteria:

* Confirmed diagnosis of ALL or lymphoblastic leukemia
* No prior therapy except short courses of corticosteroids, a single dose of IT cytarabine or emergent radiation to the mediastinum or other life-threatening masses

Exclusion Criteria:

* Have received more than 7 days of corticosteroids in the preceding 4 weeks or more than 28 days of corticosteroids in the preceding 6 months
* Have received any chemotherapy or radiotherapy for previous malignancy
* Receiving any other investigational agent
* Known to be HIV positive
* Uncontrolled intercurrent illness
* Pregnant or breastfeeding
* History of previous malignancy

Answer: C